Gabapentin is an anti-epileptic agent sold in the U.S. under 3 brand and generic names, for bipolar disorder, partial epilepsies and phobic disorders. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Gabapentin (application ANDA213603). Other gabapentin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin Capsules may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). The dose can subsequently be titrated up as needed for pain relief to a dose of 1800 mg/day (600 mg three times a day). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range; however, in these clinical studies, the additional benefit of using doses greater than 1800 mg/day was not demonstrated. 2.2 Dosage for Epilepsy with Partial Onset Seizures Patients 12 years of age and above The starting dose is 300 mg three times a day. The recommended maintenance dose of gabapentin capsules is 300 mg to 600 mg three times a day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. Administer gabapentin capsules three times a day using 300 mg or 400 mg capsules, or 600 mg or 800 mg tablets. The maximum time between doses should not exceed 12 hours. Pediatric Patients Age 3 to 11 years The starting dose range is 10 mg/kg/day to 15 mg/kg/day, given in three divided doses, and the…
The following serious adverse reactions are discussed in greater detail in other sections: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see WARNINGS AND PRECAUTIONS (5.1)] Anaphylaxis and Angioedema [see WARNINGS AND PRECAUTIONS (5.2)] Somnolence/Sedation and Dizziness [see WARNINGS AND PRECAUTIONS (5.4)] Withdrawal Precipitated Seizure, Status Epilepticus [see WARNINGS AND PRECAUTIONS (5.5)] Suicidal Behavior and Ideation [see WARNINGS AND PRECAUTIONS (5.6)] Respiratory Depression [see WARNINGS AND PRECAUTIONS (5.7)] Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) [see WARNINGS AND PRECAUTIONS (5.8)] Sudden and Unexplained Death in Patients with Epilepsy [ see WARNINGS AND PRECAUTIONS (5.10)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Postherpetic Neuralgia The most common adverse reactions associated with the use of gabapentin in adults, not seen at an equivalent frequency among placebo-treated patients, were dizziness, somnolence, and peripheral edema. In the 2 controlled trials in postherpetic neuralgia, 16% of the 336 patients who received gabapentin…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Capsule | Generic | $1 | View → | |
| 2 | Not yet rated | Prescription | Tablet | Generic | $1 | View → |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| A;469 | 100 mg | white | capsule | — |
| 215 | 300 mg | yellow | capsule | — |
| 215 | 300 mg | yellow | capsule | — |
| G;31 | 600 mg | white | oval | — |
| 216 | 100 mg | white | capsule | — |
| 215 | 300 mg | yellow |
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Gabapentin Capsules
Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .
The Harvard Drug Group LLC · Oct 10, 2025
Gabapentin Capsules
Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .
The Harvard Drug Group LLC · Oct 10, 2025
Gabapentin Capsules
Defective container; blister packaging inadequately sealed.
The Harvard Drug Group LLC · Jun 19, 2025
Gabapentin Capsules
Defective container; blister packaging inadequately sealed.
The Harvard Drug Group LLC · Jun 19, 2025
Gabapentin Tablets 600mg
CGMP Deviations
Glenmark Pharmaceuticals Inc., USA · Mar 13, 2025
The elimination half-life of gabapentin is about 5 to 7 hours in adults with normal kidney function. Gabapentin is cleared unchanged by the kidneys and is not appreciably metabolized, so there is no active metabolite and the half-life does not change with dose. However, it lengthens dramatically as kidney function drops — from about 6.5 hours to roughly 52 hours in kidney impairment, and up to about 132 hours in people with no kidney function.
NEURONTIN- gabapentin capsule (DailyMed FDA label), Clinical Pharmacology / Pharmacokinetics ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone. oxycodone, buprenorphine) [see WARNINGS AND PRECAUTIONS (5.7)]. Hydrocodone Coadministration of gabapentin with hydrocodone decreases hydrocodone exposure [see CLINICAL PHARMACOLOGY (12.3)]. The potential for alteration in hydrocodone exposure and effect should be considered when gabapentin is started or discontinued in a patient taking hydrocodone. Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression [see CLINICAL PHARMACOLOGY (12.3)]. 7.2 Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs [see CLINICAL PHARMACOLOGY (12.3)]. Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression [see CLINICAL PHARMACOLOGY (12.3)] . 7.3 Maalox ® (aluminum hydroxide, magnesium hydroxide) The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox ®) containing magnesium and aluminum hydroxides. It is recommended that gabapentin be taken at…
| 3 | Not yet rated | Prescription | Capsule | Generic | $1 | View → |
| capsule |
| — |
| 214 | 400 mg | orange | capsule | — |
|---|
| GS;TF7 | 300 mg | white | oval | — |
|---|
| GS;LFG | 600 mg | white | oval | — |
|---|